Skip to Main ContentSkip to FooterSkip to Search
Main menu
  1. Home
  2.  » 
  3. Catalent News
  4.  » Accelerated Development and Manufacturing of Oral Small Molecules to be Discussed by Catalent Applied Drug Delivery Institute and JLABS
RSS feed icon

Accelerated Development and Manufacturing of Oral Small Molecules to be Discussed by Catalent Applied Drug Delivery Institute and JLABS

SOMERSET, N.J. – March 30, 2023 — The Catalent Applied Drug Delivery Institute, which was established as a cross-industry consortium to accelerate the adoption of advanced drug delivery technologies, today announced that it will hold a symposium in affiliation with Johnson & Johnson Innovation – JLABS (JLABS), entitled “The Road to IND: Accelerating Development & Manufacturing of Oral Small Molecules”, on Tuesday, April 4, 2023, at JLABS @ San Diego. Experts and speakers from Catalent and JLABS will be joined by speakers from The Johnson & Johnson Family of Companies (Johnson & Johnson), UC San Diego, and Galileo Biosystems.

This event will bring together delegates and speakers to network and share thoughts on innovations in the oral small molecule space. It will focus on decision making in the R&D environment when developing small molecule drug products, and ensuring time, resources and funding are used efficiently to address modern biopharmaceutical challenges, and accelerate programs to the clinic with the greatest potential of success.

The events are the first of a series of events to be held in 2023 to mark the 10-year anniversary of the Catalent Applied Drug Delivery Institute, and coincides with the 90th anniversary of the softgel rotary die encapsulation technology invented by Robert Pauli Scherer (R.P. Scherer), which is the cornerstone of Catalent’s innovative softgel-based oral dose delivery portfolio.

Full details of the agenda and information on how to register for the event can be found here.




Johnson & Johnson Innovation, LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers; Johnson & Johnson Innovation—JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools and resources needed to help life science startups thrive, all with no strings attached. A Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. For more information about Johnson & Johnson Innovation, please visit:


Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.

For more information visit, and follow the Catalent Institute on Twitter: @DrugDeliveryIns


Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit


More products. Better treatments. Reliably supplied.™